Quantcast

Latest Darbepoetin alfa Stories

2011-05-18 17:05:00

THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago. These studies include data from the XGEVA® (denosumab), Vectibix® (panitumumab), ganitumab (AMG 479) and AMG 386 programs. "Amgen researchers around the globe are passionate about developing new...

2010-12-30 13:04:56

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found. The results suggest that testing such patients' responsiveness to the drug and keeping blood iron levels a little low might reduce their risk, said Dr. Robert Toto, professor of internal medicine and clinical sciences and a senior author of the study, which appeared in the New...

2010-12-08 11:41:00

BANGALORE, India, December 8, 2010 /PRNewswire/ -- AVESTHAGEN LIMITED, a leading knowledge based life sciences company pioneering the convergence between Food, Pharma and Population Genetics, today announced the completion of manufacturing of the clinical grade material of its first biosimilar molecule- AVDESP(TM) (biosimilar to Darbepoetin alfa), which will now be moving into Clinical Trials. Inno Biologics, Malaysia's biopharma CMO has successfully developed Drug Substance batches for...

2010-12-02 15:18:00

THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of...

2010-10-27 07:00:00

EXTON, Pa., Oct. 27 /PRNewswire/ -- BioTrends Research Group, Inc. released two syndicated Nephrology TreatmentTrends® publications (TreatmentTrends®: US Nephrology Q310 and TreatmentTrends®: Renal Dietitians 2010). These reports provide information gleaned from on-line surveys with 200 nephrologists and 205 renal dietitians and capture insight into attitudes, perceptions and self-reported prescribing behavior with a focus on renal...

2010-10-18 07:03:00

THOUSAND OAKS, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC). "This advisory committee...

2010-10-05 15:57:00

THOUSAND OAKS, Calif., Oct. 5 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that results from several important studies from the Company's oncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy. "Cancer is a complex disease which requires innovative therapeutic approaches. Amgen is exploring numerous biologic pathways to develop novel therapies to treat cancer and lessen the side effects of cancer...

2010-09-28 08:00:00

EXTON, Pa., Sept. 28 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrends®: The Role of Anemia Managers, Practice Managers and Facility Administrators in the Management of Renal Anemia report, based on online survey results from approximately 150 anemia managers and qualitative interviews with over 35 practice managers and facility administrators. These stakeholders are an important part of the renal anemia care team and are responsible for...

2010-07-26 07:00:00

EXTON, Pa., July 26 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrends®: US Nephrology Q2 2010 report. This quarterly report series is based on online survey results from over 100 Nephrologists and captures physician attitudes, perceptions and self-reported behavior with a focus on renal anemia and bone and mineral metabolism. In the renal anemia market, the use of erythropoietin stimulating agents (ESAs) in patients with chronic...

2010-05-20 17:08:00

THOUSAND OAKS, Calif., May 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company's oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4( )- 8, 2010 in Chicago. "Cancer is a complex disease that requires a comprehensive approach. Our goal is to help patients battle cancer by leveraging our understanding of cancer biology and pharmacogenomics to...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related